Ranbaxy Reports Higher Than Expected Loss; India Earnings Roundup
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's largest drug maker Ranbaxy, now controlled by Japan's Daiichi Sankyo, shocked financial analysts with a much higher than expected loss of 679.8 crore rupees ($142 million) during its fourth quarter as compared to a net profit of 187.80 crore ($39 million) in the corresponding quarter of 2007
You may also be interested in...
Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
The company plans to launch six to seven new products by the end of the year, and 10 additional products in 2010.
Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
The company plans to launch six to seven new products by the end of the year, and 10 additional products in 2010.
Piramal Healthcare Says Reports Of Sell-off To GSK Or Sanofi-Aventis “Totally Unfounded”
MUMBAI - Indian drug maker Piramal Healthcare has denied sell-off talks with GlaxoSmithKline or Sanofi-Aventis as is reported in the international media